Insmed, Inc. (NASDAQ:INSM) Receives $205.41 Average Price Target from Analysts

Insmed, Inc. (NASDAQ:INSM) has been given an average rating of “Moderate Buy” by the twenty-four research firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, twenty have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $205.4091.

Several research firms have weighed in on INSM. The Goldman Sachs Group boosted their price objective on Insmed from $225.00 to $258.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. HC Wainwright cut their price target on shares of Insmed from $240.00 to $230.00 and set a “buy” rating on the stock in a report on Thursday, December 18th. Citigroup restated an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Rothschild Redb upgraded shares of Insmed to a “strong-buy” rating in a report on Thursday, December 4th. Finally, UBS Group boosted their target price on shares of Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a research note on Friday, October 31st.

Insider Buying and Selling

In other Insmed news, Director Elizabeth M. Anderson sold 5,000 shares of the business’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $204.58, for a total value of $1,022,900.00. Following the sale, the director directly owned 58,729 shares in the company, valued at $12,014,778.82. The trade was a 7.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Michael Alexander Smith sold 27,130 shares of the company’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $183.78, for a total value of $4,985,951.40. Following the transaction, the insider directly owned 54,902 shares in the company, valued at $10,089,889.56. This represents a 33.07% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 157,829 shares of company stock worth $30,266,463 in the last three months. Insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Insmed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INSM. Chung Wu Investment Group LLC bought a new position in Insmed during the second quarter valued at approximately $173,000. Resolute Capital Asset Partners LLC purchased a new position in shares of Insmed in the second quarter worth about $2,748,000. Caxton Associates LLP bought a new stake in shares of Insmed in the 1st quarter valued at about $441,000. Assenagon Asset Management S.A. lifted its stake in shares of Insmed by 84.5% in the 2nd quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company’s stock valued at $7,387,000 after acquiring an additional 33,626 shares during the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new stake in Insmed during the 2nd quarter valued at about $5,578,000.

Insmed Trading Up 0.3%

Shares of INSM stock opened at $177.88 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63. The company has a market capitalization of $37.94 billion, a price-to-earnings ratio of -28.74 and a beta of 1.01. Insmed has a 52-week low of $60.40 and a 52-week high of $212.75. The company has a 50-day simple moving average of $188.95 and a two-hundred day simple moving average of $147.01.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The business had revenue of $142.34 million during the quarter, compared to analysts’ expectations of $114.33 million. Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.Insmed’s quarterly revenue was up 52.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.27) EPS. Research analysts anticipate that Insmed will post -4.56 EPS for the current fiscal year.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.